Beilu Pharmaceutical's Gadoterate Meglumine Injection Win the Bid for the 10th National Drug Centralized Procurement

2024/12/16

On December 12, 2024, Beilu Pharmaceutical participated in the bidding process for the 10th National Drug Centralized Procurement organized by the National Joint Drug Procurement Office. Beilu Pharmaceutical's Gadoterate Meglumine Injection is awarded the bid.

Related News

The Enhanced CT and Ordinary CT: Not Only to See More Clearly
May 25, 2022Enhanced CT is actually to inject some contrast agents into the patients under examination on the basis of ordinary CT. Commonly used contrast agents are iodine-containing water-soluble contrast agent...view
【Good News】Beilu Pharmaceutical once again honored as "Beijing Advanced Unit for Daily Monitoring of Adverse Drug Reactions"
July 11, 2024Recently, the Beijing Municipal Drug Administration and the Beijing Municipal Health Commission released a "Notification on Units and Individuals with Outstanding Performance in Drug, Medical Dev...view
Beilu Pharmaceutical Plans to Acquire Tianyuan Pharmaceutical, Actively Building "Second Growth Curve"
March 1, 2024Recently, Beilu Pharmaceutical announced that it plans to use its own funds to acquire 80% of the equity of Chengde Tianyuan Pharmaceutical Co., Ltd. After the completion of this acquisition, Tianyuan...view
Beilu Yikang, the R&D Subsidiary of Beilu Pharmaceutical, Was Officially Launched
October 12, 2022"Building a multi-level R&D system and actively creating a second growth curve" is the development strategy of the company, and also one of the key tasks of the company in the next few y...view
【New Product】Beilu Pharmaceutical's Paroxetine Hydrochloride Enteric-Coated Sustained-Release Tablets Approved
May 10, 2024Recently, Beilu Pharmaceutical received a Drug Registration Certificate from the National Medical Products Administration for Paroxetine Hydrochloride Enteric-Coated Sustained-Release Tablets with a s...view
Reasonable Use of Iohexol Reasonable Use of Iohexol Adverse Reactions
April 10, 2025view

Beilu Pharmaceutical's Gadoterate Meglumine Injection Win the Bid for the 10th National Drug Centralized Procurement

The Enhanced CT and Ordinary CT: Not Only to See More Clearly

【Good News】Beilu Pharmaceutical once again honored as "Beijing Advanced Unit for Daily Monitoring of Adverse Drug Reactions"

Beilu Pharmaceutical Plans to Acquire Tianyuan Pharmaceutical, Actively Building "Second Growth Curve"

Beilu Yikang, the R&D Subsidiary of Beilu Pharmaceutical, Was Officially Launched

【New Product】Beilu Pharmaceutical's Paroxetine Hydrochloride Enteric-Coated Sustained-Release Tablets Approved

Reasonable Use of Iohexol Reasonable Use of Iohexol Adverse Reactions